My name is Erianna Bass, a recent Masters of Science in Biomedical Sciences graduate from Campbell University. My goal is to obtain a clinical research management position that utilizes skills in biomedical sciences and public health experiences to improve the health and well-being of others.

http://www.pmlive.com/pharma_news/bayers_bluerock_therapeutics_gains_fda_fast_track_for_parkinsons_disease_cell_therapy_1373340

Below is a picture of a live project for a (very neat and tidy) re-install of medical gases at the NHS QEQM hospital in Margate, Kent (UK). Never has it been a more crucial time to re-think your strategy for you facilities infrastructure, whether its mechanical systems such as Gas Supply or general consultancy on best practice, Aether Medical gases are ideally pitched and equipped to assist your organisation, whether medical or lab based. I'd like to network with organisations UK wide so please get in touch luke@aethermedicalgases.co.uk
* NHS Hospital/practices
* NHS Dental Practices
* Private Hospitals/practices
* Veterinarian Practices
* Scientific Lab and Manufacturing Facilities
Please check out some case studies of Aethers work:
https://www.aethermedicalgases.com/case-studies

Freelance ■ Remote ■ Branch: Pharma ■ Project duration: 01.08.2021 - 31.12.2021+
Task description
• Perform interviews and analyze complex manufacturing processes to derive best fit recipes
(general & site)
• Work with Technical Development / Process Engineering and master the challenge to
author recipes from a variety of sources and across geographies
• Design recipes with our customers and drive them to completion including respective
workflows
• Meet with international counterparts and exchange the latest insights
Required knowledge
• Bachelor / Master in Chemical Engineering, Business Administration, Information
Technology or comparable
• Skilled in project management methodologies and biotech processes
• Expertise in the area of Enterprise Recipe Management
• Practical knowledge in the Lab or Production environment
• Very good English and German
Apply
Are you interested or do you know someone for whom the project could be interesting? I look forward to hearing from you on +49 160 915 86 941 or via e-mail at nuran.koch@ttpeurope.com

QEdge helps in manage…
I) Quality Processes,
II) Documents – controlled and uncontrolled,
III) Maintain employee training records and dossiers
#qms #qualityassurance #qualitymanagementsystem #documentmanagementsoftware #documentcontrol #documentautomation #trainingsolutions #auditmanagement

A compliant configurable endpoint solution for AUDIT READINESS
1 21 CFR Part 11 compliant
2 AI enabled eQMS
3 Enterprise wide implementation
QEdge helps in managing ...
I) Quality Processes,
II) Documents – controlled and uncontrolled,
III) Maintain employee training records and dossiers
#qms #qualityassurance #qualitymanagementsystem #documentmanagementsoftware #documentcontrol #documentautomation #trainingsolutions #auditmanagement

Leveraging smart technologies such as AI and automation can boost lab productivity by 50 to 100 percent. We at Certos enable lab device manufacturers to make smart and connected equipment by offering state-of-the-art HMI and cloud solutions.
Send us an email at info@certos.ai to receive a FREE presentation showing how we helped other manufacturers to revolutionize their devices.
Visit us here: http://www.certos.ai
https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/digitization-automation-and-online-testing-embracing-smart-quality-control

Dear PHARMeMED network,
I am excited to join this network! My name is Kevin Davies and I am COO at Certos.
Certos enables lab device manufacturers to cut IT development costs and time by up to 90% by offering a ready-to-use software framework for their equipment.
Our software uses cutting technology such as AI enabling devices to be FDA & GxP compliant.
Send us an email at info@certos.ai to receive a FREE presentation showing how we helped other manufacturers to revolutionize their devices.
Looking forward to sharing insights with you!

One of the highest standards of laboratory equipment is 21 CFR Part 11.FDA issued 21 CFR Part 11 regulations in 1997, outlined criteria for acceptance of electronic records, electronic signatures, and handwritten signatures. The regulation allows electronic records to be considered equivalent to paper records and handwritten signatures.However, there are not plentiful 21 CFR Part 11 qualified devices for one simple reason: They still have BUTTONS and SWITCHES! Their manufacturers are blocking themselves from innovation and satisfying & meeting new customers.But has your laboratory equipment fulfilled the 21 CFR Part 11?Do you want to exceed the expectations and deliver an excellent piece of laboratory equipment for your customers? We - Certos - are happy to be a partner to assist you.Visit us: http://www.certos.aiContact us: support@certos.ai

We are delighted to officially announce the launch of our brand new website,
http://www.nuvisan.com, providing our visitors an easier way to learn about NUVISAN’s solutions
from target identification to the proof of concept in patient.
For your convenience, the interactive website provides with new functionalities including an extended animated value chain easier browsing tool organized by industry or solutions, online appointment scheduling tool and a private access to your MyNUV account to allow you to easily register for our digital events, watch our videos or download our whitepapers.
Visit http://www.nuvisan.com for more.

My name is Irfan (Dir Business Development)

Freelance ■ Remote ■ Sector: Pharmaceuticals ■ From 01.09.2021 to 31.12.2023 ■ Part-time project with 800 hrs. per year
Job description and required skills
- MUST HAVE: Very good knowledge of diabetes products (BGM, CGM, IDS, Apps).
i.e. understanding why these products exist and how they work, who are the main competitors (manufacturer and brand names should be known).
- Very good Google and Excel skills
- Willingness to learn the backend of an existing platform to understand it from the ground up.
- Be able to keep track of complex issues in order to work consistently and efficiently
- Have a creative hand with screen design
- Willingness to participate in meetings / calls with colleagues from country Organisation (business fluent English is a must)
- Absolute user-orientation (usability for frontend and backend)
- Very good written and spoken German and English skills
Apply
Are you interested or do you know someone who might be interested in this project? I look forward to hearing from you on +49 160 915 86 941 or via e-mail at nuran.koch@ttpeurope.com.

Good day to all!
First off, hello! I am new to PHARMeMED. Although I'm still a student, I hope to make great and healthy connections with the professionals here.
I am currently a junior undergraduate on the degree of Medical Technology, and I am interested on entering the field of Healthcare Information System. Would anyone be able to recommend me further courses and/or certifications needed for HIS? I am open to suggestions regarding this matter. Thank you!

If your ready to define your digital strategy , Pivot Digital is all you need, Product launch is coming soon. Check out our websitehttps://www.pivotdigital.health/

Swiss pharma company Novartis has scored a Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration for its investigational radioligand therapy Lu-PSMA-617.
The BTD has been granted for Lu-PSMA-617 as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).
It was granted based on data from the Phase III VISION study, evaluating Lu-PSMA-617 plus standard of care (SoC), versus SoC alone, in patients with progressive PSMA-positive mCRPC.
In this study, Lu-PSMA-617 demonstrated a significant improvement in overall survival (OS) and radiographic progression-free survival (PFS) for men with progressive PSMA-positive mCRPC.
In the Lu-PSMA-617 arm, there was an estimated 38% reduction in the risk of death compared to the best SoC only arm.
Patients receiving Lu-PSMA-617 also demonstrated a statistically significant 60% risk reduction for radiographic PFS or death compared to best SoC only arm.
However, there was a higher rate of drug-related treatment emergent adverse events reported in the Lu-PSMA-617 treatment arm – 85.3% – compared to SoC alone – 28.8%.
Read more:https://www.pharmatimes.com/news/novartis_radioligand_therapy_granted_us_breakthrough_therapy_designation_1371903